{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T00:13:21Z","timestamp":1795220001726,"version":"4.10.3"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Phase II trial (EudraCT 2018-004562-33; NCT04131621), patients relapsed or refractory after platinum-based chemotherapy received nivolumab and ipilimumab following TMB\n                    <jats:sup>high<\/jats:sup>\n                    vs. TMB\n                    <jats:sup>low<\/jats:sup>\n                    stratification. Progression-free survival (PFS) represented the primary endpoint; overall survival (OS), response rates, duration of clinical benefit and safety were the secondary endpoints. The trial was prematurely terminated in March 2021 before reaching the preplanned sample size (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009194). Among 31 evaluable patients, 16% had a high TMB (\u2009&gt;\u200912 mutations\/Mb). Overall response rate was 16% (95% CI 6-34%), with 7.7% (95% CI 1-25%) vs. 60% (95% CI 15-95%) in TMB\n                    <jats:sup>low<\/jats:sup>\n                    and TMB\n                    <jats:sup>high<\/jats:sup>\n                    , respectively. Although the primary endpoint was not met, high TMB was associated with better median PFS (18.3 vs. 2.4 months) and OS (18.3 vs. 3.6 months). Severe immune-related adverse events were reported in 29% of cases. Assessing on-treatment dynamics of circulating tumor DNA using combined targeted hotspot mutation and shallow whole genome sequencing as part of a predefined exploratory analysis identified patients benefiting from immunotherapy irrespective of initial radiologic response.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-42400-5","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T11:30:41Z","timestamp":1698147041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-3784","authenticated-orcid":false,"given":"Maria","family":"Pouyiourou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca N.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Wohlfromm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5000-2328","authenticated-orcid":false,"given":"Boris","family":"Kubuschok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich T.","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdt","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-8263","authenticated-orcid":false,"given":"Michael","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-489X","authenticated-orcid":false,"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Sch\u00fctt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-310X","authenticated-orcid":false,"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1000-2582","authenticated-orcid":false,"given":"Stefan","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kazdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-8360","authenticated-orcid":false,"given":"Markus","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1000-8052","authenticated-orcid":false,"given":"Klaus","family":"Kluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1001-103X","authenticated-orcid":false,"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilmann","family":"Bochtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-9982","authenticated-orcid":false,"given":"Alwin","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"42400_CR1","doi-asserted-by":"crossref","unstructured":"Kr\u00e4mer, A. et al. Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 228\u2013246 (2023).","DOI":"10.1016\/j.annonc.2022.11.013"},{"key":"42400_CR2","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1200\/JCO.2003.12.104","volume":"21","author":"S Culine","year":"2003","unstructured":"Culine, S. et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J. Clin. Oncol. 21, 3479\u20133482 (2003).","journal-title":"J. Clin. Oncol."},{"key":"42400_CR3","doi-asserted-by":"publisher","unstructured":"Fizazi, K. et al. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz394 (2019).","DOI":"10.1093\/annonc\/mdz394"},{"key":"42400_CR4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41416-020-01141-8","volume":"124","author":"G Folprecht","year":"2021","unstructured":"Folprecht, G. et al. Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. Br. J. Cancer 124, 721\u2013727 (2021).","journal-title":"Br. J. Cancer"},{"key":"42400_CR5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ejca.2012.01.011","volume":"48","author":"M Gross-Goupil","year":"2012","unstructured":"Gross-Goupil, M. et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial. Eur. J. Cancer 48, 721\u2013727 (2012).","journal-title":"Eur. J. Cancer"},{"key":"42400_CR6","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/cncr.29229","volume":"121","author":"JD Hainsworth","year":"2015","unstructured":"Hainsworth, J. D. et al. Paclitaxel\/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer 121, 1654\u20131661 (2015).","journal-title":"Cancer"},{"key":"42400_CR7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/PPO.0b013e3181c6aa89","volume":"16","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth, J. D. et al. Paclitaxel\/carboplatin\/etoposide versus gemcitabine\/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site. Cancer J. 16, 70\u201375 (2010).","journal-title":"Cancer J."},{"key":"42400_CR8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","volume":"37","author":"H Hayashi","year":"2019","unstructured":"Hayashi, H., Kurata, T., Takiguchi, Y., Arai, M. & Takeda, K. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J. Clin. Oncol. 37, 570\u2013579 (2019).","journal-title":"J. Clin. Oncol."},{"key":"42400_CR9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604818","volume":"100","author":"G Huebner","year":"2009","unstructured":"Huebner, G. et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial clinical studies. Br. J. Cancer 100, 44\u201349 (2009).","journal-title":"Br. J. Cancer"},{"key":"42400_CR10","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1002\/cncr.22379","volume":"107","author":"S Palmeri","year":"2006","unstructured":"Palmeri, S. et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: Results of an Italian multicenter, randomized, phase II study. Cancer 107, 2898\u20132905 (2006).","journal-title":"Cancer"},{"key":"42400_CR11","first-page":"1455","volume":"21","author":"S Culine","year":"2001","unstructured":"Culine, S., Ycho, M., Fabbro, M., Romieu, G. & Cupissol, D. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res. 21, 1455\u20131457 (2001).","journal-title":"Anticancer Res."},{"key":"42400_CR12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1081\/CNV-100103127","volume":"19","author":"JD Hainsworth","year":"2001","unstructured":"Hainsworth, J. D. et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A Phase II trial of the Minnie Pearl Cancer Research Network. Cancer Investig. 19, 335\u2013339 (2001).","journal-title":"Cancer Investig."},{"key":"42400_CR13","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/cncr.25029","volume":"116","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth, J. D. et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: A phase 2 trial of the Sarah Cannon oncology research consortium. Cancer 116, 2448\u20132454 (2010).","journal-title":"Cancer"},{"key":"42400_CR14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1200\/JCO.2006.09.3047","volume":"25","author":"JD Hainsworth","year":"2007","unstructured":"Hainsworth, J. D. et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J. Clin. Oncol. 25, 1747\u20131752 (2007).","journal-title":"J. Clin. Oncol."},{"key":"42400_CR15","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.21416","volume":"104","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth, J. D. et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: A Minnie Pearl Cancer Research Network phase II trial. Cancer 104, 1992\u20131997 (2005).","journal-title":"Cancer"},{"key":"42400_CR16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/02841861003649240","volume":"49","author":"AKH M\u00f8ller","year":"2010","unstructured":"M\u00f8ller, A. K. H., Pedersen, K. D., Abildgaard, J., Petersen, B. L. & Daugaard, G. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncologica 49, 431\u2013435 (2010).","journal-title":"Acta Oncologica"},{"key":"42400_CR17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"42400_CR18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","volume":"94","author":"Z Gatalica","year":"2018","unstructured":"Gatalica, Z., Xiu, J., Swensen, J. & Vranic, S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur. J. Cancer 94, 179\u2013186 (2018).","journal-title":"Eur. J. Cancer"},{"key":"42400_CR19","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2016.70.5319","volume":"35","author":"LM Gay","year":"2017","unstructured":"Gay, L. M. et al. Mutational burden of tumors with primary site unknown. J. Clin. Oncol. 35, 3039\u20133039 (2017).","journal-title":"J. Clin. Oncol."},{"key":"42400_CR20","doi-asserted-by":"crossref","first-page":"e24162","DOI":"10.1200\/JCO.2018.36.15_suppl.e24162","volume":"36","author":"A Kr\u00e4mer","year":"2018","unstructured":"Kr\u00e4mer, A. et al. Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions. J. Clin. Oncol. 36, e24162\u2013e24162 (2018).","journal-title":"J. Clin. Oncol."},{"key":"42400_CR21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/gcc.23047","volume":"61","author":"T Bochtler","year":"2022","unstructured":"Bochtler, T. et al. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. Genes, Chromosomes Cancer 61, 551\u2013560 (2022).","journal-title":"Genes, Chromosomes Cancer"},{"key":"42400_CR22","doi-asserted-by":"crossref","first-page":"e2100512","DOI":"10.1200\/PO.21.00512","volume":"6","author":"MA Gouda","year":"2022","unstructured":"Gouda, M. A. et al. Longitudinal monitoring of circulating tumor DNA to predict treatment outcomes in advanced cancers. JCO Precis. Oncol. 6, e2100512 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"42400_CR23","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee, J. et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat. Med. 28, 2353\u20132363 (2022).","journal-title":"Nat. Med."},{"key":"42400_CR24","doi-asserted-by":"publisher","unstructured":"Mutter, J. A. et al. Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas. J. Clin. Oncol. JCO2200826. https:\/\/doi.org\/10.1200\/jco.22.00826 (2022).","DOI":"10.1200\/jco.22.00826"},{"key":"42400_CR25","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi, A. et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat. Med. 28, 1612\u20131618 (2022).","journal-title":"Nat. Med."},{"key":"42400_CR26","doi-asserted-by":"publisher","unstructured":"Bochtler, T. et al. Integrated clinico\u2010molecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. Int. J. Cancer 1\u201320 https:\/\/doi.org\/10.1002\/ijc.32882 (2020).","DOI":"10.1002\/ijc.32882"},{"key":"42400_CR27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"42400_CR28","doi-asserted-by":"crossref","first-page":"44322","DOI":"10.18632\/oncotarget.10035","volume":"7","author":"H L\u00f6ffler","year":"2016","unstructured":"L\u00f6ffler, H. et al. Molecular driver alterations and their clinical relevance in cancer of unknown primary site Patient characteristics. Oncotarget 7, 44322\u201344329 (2016).","journal-title":"Oncotarget"},{"key":"42400_CR29","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1002\/onco.13597","volume":"26","author":"JS Ross","year":"2021","unstructured":"Ross, J. S. et al. Comprehensive genomic profiling of carcinoma of unknown primary origin: Retrospective molecular classification considering the CUPISCO study design. Oncologist 26, e394\u2013e402 (2021).","journal-title":"Oncologist"},{"key":"42400_CR30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","volume":"41","author":"H Adderley","year":"2019","unstructured":"Adderley, H., Blackhall, F. H. & Lindsay, C. R. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. Ebiomedicine 41, 711\u2013716 (2019).","journal-title":"Ebiomedicine"},{"key":"42400_CR31","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"Z-Y Dong","year":"2017","unstructured":"Dong, Z.-Y. et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 23, 3012\u20133024 (2017).","journal-title":"Clin. Cancer Res"},{"key":"42400_CR32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33, 843\u2013852.e4 (2018).","journal-title":"Cancer Cell"},{"key":"42400_CR33","doi-asserted-by":"crossref","first-page":"602328","DOI":"10.3389\/fmolb.2020.602328","volume":"7","author":"X Lin","year":"2020","unstructured":"Lin, X. et al. Prognostic biomarker TP53 mutations for immune checkpoint blockade therapy and its association with tumor microenvironment of lung adenocarcinoma. Front. Mol. Biosci. 7, 602328 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"42400_CR34","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"42400_CR35","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","volume":"26","author":"B Ricciuti","year":"2020","unstructured":"Ricciuti, B. et al. Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non\u2013small cell lung cancer. Clin. Cancer Res. 26, 4135\u20134142 (2020).","journal-title":"Clin. Cancer Res."},{"key":"42400_CR36","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo, M. Y. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit From PD-1\/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685\u20131694 (2018).","journal-title":"J. Clin. Oncol."},{"key":"42400_CR37","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","volume":"3","author":"FM Barriga","year":"2022","unstructured":"Barriga, F. M. et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nat. Cancer 3, 1367\u20131385 (2022).","journal-title":"Nat. Cancer"},{"key":"42400_CR38","volume":"12","author":"G Han","year":"2021","unstructured":"Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 5606 (2021).","journal-title":"Nat. Commun."},{"key":"42400_CR39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jnci\/djx271","volume":"110","author":"S Horn","year":"2018","unstructured":"Horn, S. et al. Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance. JNCI: J. Natl Cancer Inst. 110, 677\u2013681 (2018).","journal-title":"JNCI: J. Natl Cancer Inst."},{"key":"42400_CR40","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.annonc.2020.02.017","volume":"31","author":"G Lamberti","year":"2020","unstructured":"Lamberti, G. et al. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann. Oncol. 31, 807\u2013814 (2020).","journal-title":"Ann. Oncol."},{"key":"42400_CR41","doi-asserted-by":"crossref","first-page":"71249","DOI":"10.18632\/oncotarget.19531","volume":"8","author":"RFV Medrano","year":"2017","unstructured":"Medrano, R. F. V. et al. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 8, 71249\u201371284 (2017).","journal-title":"Oncotarget"},{"key":"42400_CR42","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.neo.2021.08.004","volume":"23","author":"A Razaghi","year":"2021","unstructured":"Razaghi, A., Brusselaers, N., Bj\u00f6rnstedt, M. & Durand-Dubief, M. Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy. Neoplasia 23, 1059\u20131068 (2021).","journal-title":"Neoplasia"},{"key":"42400_CR43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","volume":"17","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J. Thorac. Oncol. 17, 399\u2013410 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"42400_CR44","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis, F. et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822\u2013835 (2018). CD-18-0099.","journal-title":"Cancer Discov."},{"key":"42400_CR45","doi-asserted-by":"crossref","first-page":"1860586","DOI":"10.1080\/2162402X.2020.1860586","volume":"10","author":"J Budczies","year":"2021","unstructured":"Budczies, J. et al. A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. OncoImmunology 10, 1860586 (2021).","journal-title":"OncoImmunology"},{"key":"42400_CR46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher, P. et al. Gene expression markers of tumor infiltrating leukocytes. J. Immunother. Cancer 5, 18 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"42400_CR47","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41588-022-01235-4","volume":"54","author":"LF Spurr","year":"2022","unstructured":"Spurr, L. F., Weichselbaum, R. R. & Pitroda, S. P. Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat. Genet. 54, 1782\u20131785 (2022).","journal-title":"Nat. Genet."},{"key":"42400_CR48","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676\u2013689.e3 (2018).","journal-title":"Cancer Cell"},{"key":"42400_CR49","doi-asserted-by":"crossref","first-page":"e003402","DOI":"10.1136\/jitc-2021-003402","volume":"10","author":"NB Collins","year":"2022","unstructured":"Collins, N. B. et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J. Immunother. Cancer 10, e003402 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"42400_CR50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004822","volume":"10","author":"KP Raghav","year":"2022","unstructured":"Raghav, K. P. et al. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J. Immunother. Cancer 10, e004822 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"42400_CR51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","volume":"33","author":"J Tanizaki","year":"2022","unstructured":"Tanizaki, J. et al. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann. Oncol. 33, 216\u2013226 (2022).","journal-title":"Ann. Oncol."},{"key":"42400_CR52","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.annonc.2022.05.008","volume":"33","author":"Y Sasaki","year":"2022","unstructured":"Sasaki, Y., Sakaguchi, C. & Satoh, E. Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval? Ann. Oncol. 33, 984\u2013985 (2022).","journal-title":"Ann. Oncol."},{"key":"42400_CR53","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.32645","volume":"126","author":"AR Khaki","year":"2020","unstructured":"Khaki, A. R. et al. Impact of performance status on treatment outcomes: A real\u2010world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer 126, 1208\u20131216 (2020).","journal-title":"Cancer"},{"key":"42400_CR54","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/cncr.32782","volume":"126","author":"LA Petrillo","year":"2020","unstructured":"Petrillo, L. A. et al. Performance status and end\u2010of\u2010life care among adults with non\u2013small cell lung cancer receiving immune checkpoint inhibitors. Cancer 126, 2288\u20132295 (2020).","journal-title":"Cancer"},{"key":"42400_CR55","doi-asserted-by":"crossref","first-page":"e2037120","DOI":"10.1001\/jamanetworkopen.2020.37120","volume":"4","author":"K Sehgal","year":"2021","unstructured":"Sehgal, K. et al. Association of performance status with survival in patients with advanced non\u2013small cell lung cancer treated with pembrolizumab monotherapy. Jama Netw. Open 4, e2037120 (2021).","journal-title":"Jama Netw. Open"},{"key":"42400_CR56","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.anl.2020.01.003","volume":"47","author":"H Inoue","year":"2020","unstructured":"Inoue, H. et al. Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. Auris Nasus Larynx 47, 650\u2013657 (2020).","journal-title":"Auris Nasus Larynx"},{"key":"42400_CR57","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 24, 4960\u20134967 (2018).","journal-title":"Clin. Cancer Res."},{"key":"42400_CR58","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.13180","volume":"39","author":"M Katsurada","year":"2019","unstructured":"Katsurada, M. et al. Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer. Anticancer Res. 39, 815\u2013825 (2019).","journal-title":"Anticancer Res."},{"key":"42400_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-18611-z","volume":"12","author":"T Matoba","year":"2022","unstructured":"Matoba, T. et al. Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors. Sci. Rep. 12, 1\u20138 (2022).","journal-title":"Sci. Rep."},{"key":"42400_CR60","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/j.cllc.2020.02.012","volume":"21","author":"T Miyawaki","year":"2020","unstructured":"Miyawaki, T. et al. Association between clinical tumor burden and efficacy of immune checkpoint inhibitor monotherapy for advanced non\u2013small-cell lung cancer. Clin. Lung Cancer 21, e405\u2013e414 (2020).","journal-title":"Clin. Lung Cancer"},{"key":"42400_CR61","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1634\/theoncologist.2020-0014","volume":"25","author":"F Pietrantonio","year":"2020","unstructured":"Pietrantonio, F. et al. Efficacy and safety of immune checkpoint inhibitors in patients with microsatellite instability\u2010high end\u2010stage cancers and poor performance status related to high disease burden. Oncol 25, 803\u2013809 (2020).","journal-title":"Oncol"},{"key":"42400_CR62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","volume":"14","author":"KS Button","year":"2013","unstructured":"Button, K. S. et al. Power failure: Why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 14, 365\u2013376 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"42400_CR63","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jclinepi.2011.06.016","volume":"64","author":"EW Steyerberg","year":"2011","unstructured":"Steyerberg, E. W., Schemper, M. & Harrell, F. E. Logistic regression modeling and the number of events per variable: selection bias dominates. J. Clin. Epidemiol. 64, 1464\u20131465 (2011).","journal-title":"J. Clin. Epidemiol."},{"key":"42400_CR64","doi-asserted-by":"publisher","unstructured":"Brahmer, J. R. et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in CheckMate 227. J. Clin. Oncol. 101200JCO2201503. https:\/\/doi.org\/10.1200\/jco.22.01503 (2022).","DOI":"10.1200\/jco.22.01503"},{"key":"42400_CR65","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"42400_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/ mismatch repair\u2013deficient cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol."},{"key":"42400_CR67","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer\u2013immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"42400_CR68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","volume":"53","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat. Genet. 53, 11\u201315 (2021).","journal-title":"Nat. Genet."},{"key":"42400_CR69","doi-asserted-by":"publisher","unstructured":"Serritella, A. V. & Shenoy, N. K. Nivolumab plus ipilimumab vs nivolumab alone in advanced cancers other than melanoma. JAMA Oncol. 9, https:\/\/doi.org\/10.1001\/jamaoncol.2023.3295 (2023). Published online August 31, 2023.","DOI":"10.1001\/jamaoncol.2023.3295"},{"key":"42400_CR70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial. Lancet (Lond., Engl.) 398, 27 (2021).","journal-title":"Lancet (Lond., Engl.)"},{"key":"42400_CR71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","volume":"40","author":"D-Y Oh","year":"2022","unstructured":"Oh, D.-Y. et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J. Clin. Oncol. 40, 378\u2013378 (2022).","journal-title":"J. Clin. Oncol."},{"key":"42400_CR72","doi-asserted-by":"publisher","unstructured":"Oh, D.-Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence 1, https:\/\/doi.org\/10.1056\/EVIDoa2200015 (2022).","DOI":"10.1056\/EVIDoa2200015"},{"key":"42400_CR73","doi-asserted-by":"crossref","first-page":"e769","DOI":"10.1002\/onco.13744","volume":"26","author":"C Pauli","year":"2021","unstructured":"Pauli, C. et al. A challenging task: Identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: The CUPISCO trial experience. Oncologist 26, e769\u2013e779 (2021).","journal-title":"Oncologist"},{"key":"42400_CR74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2307\/2531201","volume":"42","author":"JM Lachin","year":"1986","unstructured":"Lachin, J. M. & Foulkes, M. A. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42, 507\u2013519 (1986).","journal-title":"Biometrics"},{"key":"42400_CR75","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jmoldx.2020.02.009","volume":"22","author":"LI Kroeze","year":"2020","unstructured":"Kroeze, L. I. et al. Evaluation of a hybrid capture\u2013based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes. J. Mol. Diagnostics 22, 757\u2013769 (2020).","journal-title":"J. Mol. Diagnostics"},{"key":"42400_CR76","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jtho.2020.01.023","volume":"15","author":"A Stenzinger","year":"2020","unstructured":"Stenzinger, A. et al. Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study. J. Thorac. Oncol. 15, 1177\u20131189 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"42400_CR77","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ijc.32133","volume":"145","author":"A Volckmar","year":"2019","unstructured":"Volckmar, A. et al. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3000 Heidelberg cases. Int. J. Cancer 145, 649\u2013661 (2019).","journal-title":"Int. J. Cancer"},{"key":"42400_CR78","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469\u2013474 (2018).","journal-title":"Nature"},{"key":"42400_CR79","unstructured":"Hovestadt, V. & Zapatka, M. conumee: Enhanced copy-number variation analysis using Illumina DNA methylation arrays. https:\/\/bioconductor.org\/packages\/release\/bioc\/html\/conumee.html."},{"key":"42400_CR80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jbiotec.2017.08.006","volume":"261","author":"E Reisinger","year":"2017","unstructured":"Reisinger, E. et al. OTP: An automatized system for managing and processing NGS data. J. Biotechnol. 261, 53\u201362 (2017).","journal-title":"J. Biotechnol."},{"key":"42400_CR81","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108\u2013e108 (2013).","journal-title":"Nucleic Acids Res"},{"key":"42400_CR82","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gr.209601.116","volume":"27","author":"T Smith","year":"2017","unstructured":"Smith, T., Heger, A. & Sudbery, I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res. 27, 491\u2013499 (2017).","journal-title":"Genome Res."},{"key":"42400_CR83","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42400-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T21:21:01Z","timestamp":1700169661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42400-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42400"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-42400-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. received consultation fees and honoraria from BMS. B.K. received grants\/research support from Roche, Morphosys, MSD and Hexal, and honoraria from Roche. U.T.H. received grants\/research support from Celgene and Roche, and honoraria from Roche, Servier, Novartis and Merck Serono. G.H. received consultation fees from Roche and AstraZeneca, and honoraria from Roche, Amgen, Pierre-Fabre, AstraZeneca, Alexion, Servier, Octapharma, Abbvie, GSK and Beigene. L.W. received honoraria from Roche and Servier and travel support from Amgen. M.B. received consultation fees from Roche, Incyte, Bayer, MSD and Ipsen. A.S. received grants\/research support from Bayer, BMS, Chugai and Incyte, and consultation fees\/honoraria from Aignostics, Amgen, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, Roche, Seattle Genetics, Takeda and Thermo Fisher. T.B. has worked as a study oncologist for the CUPISCO trial, which is sponsored by Roche and has received reimbursement for study-related travels as well as remuneration for his work as a study oncologist for the benefit of his employer. A.K. received consultation fees and honoraria from Roche and grants\/research support from BMS and Molecular Health. All remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6761"}}